• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

从单个癌细胞快速产生的药物反应异质性证据。

Evidence of drug-response heterogeneity rapidly generated from a single cancer cell.

作者信息

Wang Rong, Jin Chengmeng, Hu Xun

机构信息

Cancer Institute, A Key Laboratory For Cancer Prevention & Intervention, Ministry of Education of the People's Republic of China, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.

出版信息

Oncotarget. 2017 Jun 20;8(25):41113-41124. doi: 10.18632/oncotarget.17064.

DOI:10.18632/oncotarget.17064
PMID:28467802
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5522224/
Abstract

One cancer cell line is believed to be composed of numerous clones with different drug sensitivity. We sought to investigate the difference of drug-response pattern in clones from a cell line or from a single cell. We showed that 22 clones derived from 4T1 cells were drastically different from each other with respect to drug-response pattern against 11 anticancer drugs and expression profile of 19 genes associated with drug resistance or sensitivity. Similar results were obtained using daughter clones derived from a single 4T1 cell. Each daughter clone showed distinct drug-response pattern and gene expression profile. Similar results were also obtained using Bcap37 cells. We conclude that a single cancer cell can rapidly produce a population of cells with high heterogeneity of drug response and the acquisition of drug-response heterogeneity is random.

摘要

一种癌细胞系被认为是由许多具有不同药物敏感性的克隆组成。我们试图研究来自同一细胞系或单个细胞的克隆在药物反应模式上的差异。我们发现，从4T1细胞衍生出的22个克隆在对11种抗癌药物的反应模式以及19个与耐药性或敏感性相关基因的表达谱方面彼此差异巨大。使用从单个4T1细胞衍生出的子克隆也获得了类似结果。每个子克隆都表现出独特的药物反应模式和基因表达谱。使用Bcap37细胞也得到了类似结果。我们得出结论，单个癌细胞能够迅速产生一群具有高度药物反应异质性的细胞，并且药物反应异质性的获得是随机的。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/abebe5c07e6d/oncotarget-08-41113-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/af9fe396f96b/oncotarget-08-41113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/34406922381f/oncotarget-08-41113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/b6db5bb11b0f/oncotarget-08-41113-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/0628c528d690/oncotarget-08-41113-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/fd14e8469fe1/oncotarget-08-41113-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/97eeb811fc76/oncotarget-08-41113-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/71ac65ed79d3/oncotarget-08-41113-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/abebe5c07e6d/oncotarget-08-41113-g008.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/af9fe396f96b/oncotarget-08-41113-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/34406922381f/oncotarget-08-41113-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/b6db5bb11b0f/oncotarget-08-41113-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/0628c528d690/oncotarget-08-41113-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/fd14e8469fe1/oncotarget-08-41113-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/97eeb811fc76/oncotarget-08-41113-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/71ac65ed79d3/oncotarget-08-41113-g007.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/30bb/5522224/abebe5c07e6d/oncotarget-08-41113-g008.jpg

相似文献

1
Evidence of drug-response heterogeneity rapidly generated from a single cancer cell.从单个癌细胞快速产生的药物反应异质性证据。
Oncotarget. 2017 Jun 20;8(25):41113-41124. doi: 10.18632/oncotarget.17064.
2
Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapy.利妥昔单抗耐药B-NHL克隆的发展：一种用于研究肿瘤对单克隆抗体介导免疫疗法耐药性的体外模型。
Methods Mol Biol. 2011;731:407-19. doi: 10.1007/978-1-61779-080-5_33.
3
Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity.化疗诱导衰老，一种驱动耐药性和肿瘤异质性的适应性机制。
Cell Cycle. 2019 Oct;18(19):2385-2397. doi: 10.1080/15384101.2019.1652047. Epub 2019 Aug 9.
4
Heterogeneity of molecular targets on clonal cancer lines derived from a novel hormone-refractory prostate cancer tumor system.源自新型激素难治性前列腺癌肿瘤系统的克隆癌细胞系上分子靶点的异质性
Prostate. 2003 Jun 1;55(4):299-307. doi: 10.1002/pros.10226.
5
Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.乳腺癌细胞对化疗诱导的单步衰老的逃避：对治疗反应的影响。
Clin Cancer Res. 2005 Apr 1;11(7):2637-43. doi: 10.1158/1078-0432.CCR-04-1462.
6
Differential effects of retinoic acid on the growth of isogenic metastatic and non-metastatic breast cancer cell lines and their association with distinct expression of retinoic acid receptor beta isoforms 2 and 4.视黄酸对同基因转移性和非转移性乳腺癌细胞系生长的不同影响及其与视黄酸受体β亚型2和4的不同表达的关联。
Int J Oncol. 2003 Mar;22(3):623-9.
7
Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma.人类黑色素瘤中 CTA 表达谱的表观遗传调控克隆遗传。
J Cell Physiol. 2010 May;223(2):352-8. doi: 10.1002/jcp.22040.
8
Use of a Combined Gene Expression Profile in Implementing a Drug Sensitivity Predictive Model for Breast Cancer.联合基因表达谱在构建乳腺癌药物敏感性预测模型中的应用
Cancer Res Treat. 2017 Jan;49(1):116-128. doi: 10.4143/crt.2016.085. Epub 2016 May 18.
9
Improvement of sensitivity to platinum compound with siRNA knockdown of upregulated genes in platinum complex-resistant ovarian cancer cells in vitro.体外通过siRNA敲低铂类复合物耐药卵巢癌细胞中上调基因来提高对铂类化合物的敏感性。
Biomed Pharmacother. 2009 Sep;63(8):553-60. doi: 10.1016/j.biopha.2008.04.006. Epub 2008 May 27.
10
A gene expression database for the molecular pharmacology of cancer.一个用于癌症分子药理学的基因表达数据库。
Nat Genet. 2000 Mar;24(3):236-44. doi: 10.1038/73439.

引用本文的文献

1
Bax- Bcl-xL interaction dynamics during the progression of cell cycle and cell death using FLIM-FRET.利用荧光寿命成像-荧光共振能量转移技术研究细胞周期进程和细胞死亡过程中Bax与Bcl-xL的相互作用动力学
Cell Stress. 2025 Jul 8;9:143-157. doi: 10.15698/cst2025.07.307. eCollection 2025.
2
Stochastic pharmacodynamics of a heterogeneous tumour-cell population.异质性肿瘤细胞群体的随机药效学。
J Pharmacokinet Pharmacodyn. 2025 May 5;52(3):28. doi: 10.1007/s10928-025-09974-7.
3
Relatively Rare Populations of Invasive Cells Drive Progression of Heterogeneous Tumors.

本文引用的文献

1
Lactic acidosis switches cancer cells from aerobic glycolysis back to dominant oxidative phosphorylation.乳酸酸中毒使癌细胞从有氧糖酵解转变回以氧化磷酸化为主。
Oncotarget. 2016 Jun 28;7(26):40621-40629. doi: 10.18632/oncotarget.9746.
2
Metastatic model of HPV+ oropharyngeal squamous cell carcinoma demonstrates heterogeneity in tumor metastasis.人乳头瘤病毒阳性口咽鳞状细胞癌的转移模型显示出肿瘤转移的异质性。
Oncotarget. 2016 Apr 26;7(17):24194-207. doi: 10.18632/oncotarget.8254.
3
Evidence That Does Not Support Pyruvate Kinase M2 (PKM2)-catalyzed Reaction as a Rate-limiting Step in Cancer Cell Glycolysis.
相对罕见的侵袭性细胞群体驱动异质性肿瘤的进展。
Cell Mol Bioeng. 2024 Jan 5;17(1):7-24. doi: 10.1007/s12195-023-00792-w. eCollection 2024 Feb.
4
Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.胱氨酸/谷氨酸反向转运蛋白 xCT 缺乏可减少乳腺癌小鼠模型的转移，而不损害免疫系统功能。
J Exp Clin Cancer Res. 2023 Sep 29;42(1):254. doi: 10.1186/s13046-023-02830-x.
5
The CellPhe toolkit for cell phenotyping using time-lapse imaging and pattern recognition.使用延时成像和模式识别进行细胞表型分析的 CellPhe 工具包。
Nat Commun. 2023 Apr 3;14(1):1854. doi: 10.1038/s41467-023-37447-3.
6
CeDR Atlas: a knowledgebase of cellular drug response.CeDR 图谱：细胞药物反应知识库。
Nucleic Acids Res. 2022 Jan 7;50(D1):D1164-D1171. doi: 10.1093/nar/gkab897.
7
Beyond Deterministic Models in Drug Discovery and Development.超越药物发现和开发中的确定性模型。
Trends Pharmacol Sci. 2020 Nov;41(11):882-895. doi: 10.1016/j.tips.2020.09.005. Epub 2020 Oct 5.
8
Synthesis, characterization, DNA binding, topoisomerase inhibition, and apoptosis induction studies of a novel cobalt(III) complex with a thiosemicarbazone ligand.新型钴(III)配合物的合成、表征、DNA 结合、拓扑异构酶抑制和凋亡诱导研究，该配合物的配体为硫代半卡巴腙。
J Inorg Biochem. 2020 Feb;203:110907. doi: 10.1016/j.jinorgbio.2019.110907. Epub 2019 Nov 2.
9
Activation of Piezo1 sensitizes cells to TRAIL-mediated apoptosis through mitochondrial outer membrane permeability.Piezo1 的激活通过线粒体膜通透性使细胞对 TRAIL 介导的细胞凋亡敏感。
Cell Death Dis. 2019 Nov 4;10(11):837. doi: 10.1038/s41419-019-2063-6.
10
Hyperthermia enhances photodynamic therapy by regulation of HCP1 and ABCG2 expressions via high level ROS generation.高热通过高水平 ROS 生成调控 HCP1 和 ABCG2 的表达增强光动力治疗。
Sci Rep. 2019 Feb 7;9(1):1638. doi: 10.1038/s41598-018-38460-z.
不支持丙酮酸激酶M2（PKM2）催化反应作为癌细胞糖酵解限速步骤的证据。
J Biol Chem. 2016 Apr 22;291(17):8987-99. doi: 10.1074/jbc.M115.704825. Epub 2016 Feb 25.
4
Multipotent luminal mammary cancer stem cells model tumor heterogeneity.多能性管腔型乳腺癌干细胞可模拟肿瘤异质性。
Breast Cancer Res. 2015 Oct 14;17(1):137. doi: 10.1186/s13058-015-0615-y.
5
Single-cell mRNA sequencing identifies subclonal heterogeneity in anti-cancer drug responses of lung adenocarcinoma cells.单细胞mRNA测序揭示了肺腺癌细胞抗癌药物反应中的亚克隆异质性。
Genome Biol. 2015 Jun 19;16(1):127. doi: 10.1186/s13059-015-0692-3.
6
Biological and therapeutic impact of intratumor heterogeneity in cancer evolution.肿瘤内异质性在癌症进化中的生物学和治疗影响。
Cancer Cell. 2015 Jan 12;27(1):15-26. doi: 10.1016/j.ccell.2014.12.001.
7
Single cell-derived clonal analysis of human glioblastoma links functional and genomic heterogeneity.人胶质母细胞瘤的单细胞克隆分析揭示了功能和基因组的异质性。
Proc Natl Acad Sci U S A. 2015 Jan 20;112(3):851-6. doi: 10.1073/pnas.1320611111. Epub 2015 Jan 5.
8
Deciphering intratumor heterogeneity and temporal acquisition of driver events to refine precision medicine.解析肿瘤内异质性和驱动事件的时间性获得以优化精准医学。
Genome Biol. 2014 Aug 27;15(8):453. doi: 10.1186/s13059-014-0453-8.
9
From cancer genomics to precision oncology--tissue's still an issue.从癌症基因组学到精准肿瘤学——组织仍然是个问题。
Cell. 2014 Jun 19;157(7):1509-14. doi: 10.1016/j.cell.2014.05.027.
10
No evident dose-response relationship between cellular ROS level and its cytotoxicity--a paradoxical issue in ROS-based cancer therapy.细胞活性氧水平与其细胞毒性之间无明显剂量反应关系——基于活性氧的癌症治疗中的一个矛盾问题。
Sci Rep. 2014 May 22;4:5029. doi: 10.1038/srep05029.